OncoImmuno

Executive Summary

OncoImmuno is a private biotechnology company pioneering next-generation multi-specific antibody therapies for oncology and immunology. Founded in 2017 and headquartered in New York, the company leverages a proprietary platform to engineer antibodies with enhanced efficacy and reduced toxicity, aiming to engage the immune system more effectively against cancer and autoimmune diseases. With $580 million raised to date, OncoImmuno is well-capitalized to advance its pipeline through clinical development. The company is currently in Phase 1, with lead candidates designed to address unmet needs in solid tumors and inflammatory conditions. Its platform technology differentiates it by enabling multi-target engagement, potentially overcoming resistance mechanisms seen with conventional monoclonal antibodies. While still in early clinical stages, the strong financial backing and innovative approach position OncoImmuno as a notable player in the immuno-oncology space. The management team has a track record of advancing biologics from discovery through regulatory milestones, and the company is actively expanding its pipeline with additional indications.

Upcoming Catalysts (preview)

• TBDPhase 1 interim data readout for lead bispecific antibody70% success
• TBDIND submission for next-generation autoimmune candidate80% success
• TBDStrategic partnership or licensing deal for platform technology60% success